MarketsandMarkets™ has added a new report titled, ‘Global Single use Bioprocessing Market’ in its vast database of research reports. The Global Single-use Bioprocessing Market is thoroughly analyzed in this report, providing valuable insights into its current landscape and future growth prospects. The report covers the forecast period of 2021 to 2026 and offers a comprehensive overview of the market by utilizing a meticulous approach that involves studying, synthesizing, and consolidating data from multiple reliable sources. With the aim of accurately determining the market size, the report presents a detailed analysis of key factors and trends driving the growth of the single-use bioprocessing market. The findings of this report serve as a valuable resource for industry stakeholders, researchers, and decision-makers seeking to understand the dynamics of the global single-use bioprocessing market and make informed business decisions.
The report is helpful to everyone, right from an expert, professional, analyst, employee to a manager. This report contains statistical data that enables the reader to have a detailed summary and the overall insights, which can be applied in the decision-making process, taking into consideration the core and crucial business areas. The report also contains some illustrations and presentations, in the form of charts, graphs, and tables, along with qualitative and quantitative data, so as to understand and gain insights. The report also helps the readers by availing the ready-to-access analytical data provided by the industry experts.
Download a PDF Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297
The report "Single use Bioprocessing Market Size, Growth by Product (Media Bags and containers, Bioreactors, Mixers, Assemblies), Application (Cell Culture, Mixing, Storage, Filtration, Purification), End User (Biopharma Companies, CROs, CMOs) - Global Forecast 2026", is projected to reach USD 20.8 billion by 2026, at a CAGR of 20.5%.
The single-use bioprocessing market is highly consolidated with majority of the market share taken up by key players such as Thermo Fisher Scientific (US), Danaher Corporation (US), Sartorius Stedim Biotech S.A. (France), and Merck KGaA (Germany). The key players in this market are increasingly focusing on strategic expansions, partnerships, and product approvals to expand their manufacturing capabilities and increase market presence.
This study categorizes the global single use bioprocessing market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- Single-use media bags and containers
- Single-use assemblies
- Single-use bioreactors
- Disposable mixers
- Other products
By Application
- Filtration
- Storage
- Cell culture
- Mixing
- Purification
By End user
- Biopharmaceutical Pharmaceutical companies
- Contract Research Organizations and contract manufacturing organizations (CROs CMOs)
- Academic Research institutes
Some of the key geographies mentioned in this report include:
- North America (U.S and Canada and rest of North America)
- Europe (Germany, France, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
- LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)
Hypothetic Challenges of Single use Bioprocessing Market in Near Future:
- Regulatory Challenges: As the use of single-use bioprocessing technologies becomes more widespread, regulatory bodies may need to develop new guidelines and standards for their use. This could create uncertainty and delay in the adoption of these technologies.
- Supply Chain Disruptions: The COVID-19 pandemic has highlighted the fragility of global supply chains. If there are disruptions in the supply of raw materials or components needed for single-use bioprocessing systems, this could lead to delays and increased costs for manufacturers.
- Environmental Concerns: While single-use bioprocessing systems offer several advantages over traditional stainless-steel systems, they also generate more waste. There may be increasing pressure from regulators and consumers to reduce waste and increase sustainability in the biopharmaceutical industry.
- Cost: While single-use bioprocessing systems offer several advantages, they can be more expensive than traditional stainless-steel systems. This may limit their adoption in certain markets or by smaller biopharmaceutical companies.
- Technology Limitations: While single-use bioprocessing systems have advanced significantly in recent years, there may still be limitations in their performance and scalability for certain applications. This could limit their adoption in certain markets or by certain biopharmaceutical companies.
Top 3 Use Cases of Single use Bioprocessing Market:
- Cell Culture: Single-use bioreactors and other disposable technologies are widely used in cell culture for the production of biologics, such as monoclonal antibodies and recombinant proteins. These systems offer several advantages over traditional stainless-steel systems, including reduced cleaning and validation time, increased flexibility, and reduced risk of cross-contamination.
- Downstream Processing: Single-use chromatography systems and other disposable technologies are used in downstream processing to purify and concentrate biologic products. These systems offer several advantages over traditional stainless-steel systems, including reduced cleaning and validation time, increased flexibility, and reduced risk of cross-contamination.
- Vaccine Production: Single-use bioprocessing technologies are increasingly being used for the production of vaccines. These technologies offer several advantages over traditional stainless-steel systems, including reduced cleaning and validation time, increased flexibility, and reduced risk of cross-contamination. Additionally, single-use bioprocessing systems are well-suited for the rapid production of vaccines in response to outbreaks or pandemics.
Recent Developments:
- In March 2020, Danaher acquired the Biopharma business from General Electric Company's Life Sciences division. The business is called Cytiva and is a standalone operating company within Danaher's Life Sciences segment.
- In September 2020, Thermo Fisher Scientific invested more than USD 475 million in new capabilities at its St. Louis site to expand biologics development and manufacturing, cell and gene therapy capabilities, and drug product development capabilities.
Content Source:
https://www.marketsandmarkets.com/PressReleases/single-use-bioprocessing.asp
https://www.marketsandmarkets.com/ResearchInsight/single-use-bioprocessing-market.asp
Related Reports:
